CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
Authors:
Open Access
- 22 November 2023
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-13
Abstract
Background: Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40–60%) still fail to respond or relapse due to the development of resistance. Alterations in the expression of Human Leukocyte Antigen class I (HLA-I) molecules are considered to play a major role in clinical resistance to ICI. Cellular immunotherapy with HLA-independent CAR-redirected lymphocytes is a promising alternative in this challenging setting and dedicated translational models are needed. Methods: In this study, we propose an HLA-independent therapeutic strategy with Cytokine Induced Killer lymphocytes (CIK) genetically engineered with a Chimeric Antigen Receptor (CAR) targeting the tumor antigen CSPG4 as effector mechanism. We investigated the preclinical antitumor activity of CSPG4-CAR.CIK in vitro and in a xenograft murine model focusing on patient-derived melanoma cell lines (Mel) with defective expression of HLA-I molecules. Results: We successfully generated CSPG4-CAR.CIK from patients with metastatic melanoma and reported their intense activity in vitro against a panel of CSPG4-expressing patient-derived Mel. The melanoma killing activity was intense, even at very low effector to target ratios, and not influenced by the expression level (high, low, defective) of HLA-I molecules on target cells. Furthermore, CAR.CIK conditioned medium was capable of upregulating the expression of HLA-I molecules on melanoma cells. A comparable immunomodulatory effect was replicated by treatment of Mel cells with exogenous IFN-γ and IFN-α. The antimelanoma activity of CSPG4-CAR.CIK was successfully confirmed in vivo, obtaining a significant tumor growth inhibition of an HLA-defective Mel xenograft in immunodeficient mice. Conclusions: In this study we reported the intense preclinical activity of CSPG4-CAR.CIK against melanoma, including those with low or defective HLA-I expression. Our findings support CSPG4 as a valuable CAR target in melanoma and provide translational rationale for clinical studies exploring CAR-CIK cellular immunotherapies within the challenging setting of patients not responsive or relapsing to immune checkpoint inhibitors.Keywords
Funding Information
- Ministero della Salute (Ricerca Corrente 2023, Progetto CAR-T RCR-2019-23669115)
- Associazione Italiana per la Ricerca sul Cancro (IG-2017 20259)
- Università degli Studi di Torino (Fondo Ricerca Locale 2022)
This publication has 42 references indexed in Scilit:
- Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanomaCancer Immunology, Immunotherapy, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumorsExpert Opinion on Therapeutic Targets, 2015
- Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue SarcomasCancer Research, 2014
- Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness FeaturesClinical Cancer Research, 2013
- Human Leukocyte Antigen (HLA) Typing by DNA Sequencing2013
- Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitroJournal of Experimental & Clinical Cancer Research, 2010
- CSPG4 in Cancer: Multiple RolesCurrent Molecular Medicine, 2010
- Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriersInternational Immunology, 2008
- Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophagesNature Immunology, 2000